Jefferies raised the firm’s price target on Monte Rosa Therapeutics (GLUE) to $31 from $22 and keeps a Buy rating on the shares after MRT-8102 showed deep reduction of inflammatory biomarker hsCRP in healthy volunteers and subjects with elevated cardiovascular risk in a Phase 1 study. The firm sees the data providing “strong” early proof of concept with broad potential across cardiometabolic diseases, the analyst tells investors.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GLUE:
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!
- Midday Fly By: Warner Bros. urges holders to reject Paramount bid
- Monte Rosa data position MRT-8102 ‘favorably,’ says LifeSci Capital
- Monte Rosa Therapeutics price target raised to $37 from $26 at Wedbush
- Here’s Why Monte Rosa Therapeutics Stock (GLUE) Rocketed Today